TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rectal CSA during stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rectal pressure-CSA relation during stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Physiological stress indication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients requiring meperidine injection for pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEPs amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified pulmonary index score (MPIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EDSS from baseline to 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualised relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to EDSS progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apoptosis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of miR‐15a and miR‐16‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferation of CNE‐2Z cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of peritoneal tears
Endpoint domain: Adverse events/effects
Primary endpoint: Need for postoperative analgesics
Endpoint domain: Adverse events/effects
Primary endpoint: Fasting glucose and insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patient acceptance rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage reduction in seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of PSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of postoperative nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of antiemetic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to execute movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day cumulative rebleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative rebleeding-free proportion between the 8th and 28th day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in treating OCD and anxiety disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage agreement of positive reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: preoperative hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: consumption of general anesthetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in serum interleukin 6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leukocyte and platelet counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Wound healing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary trypsin inhibitory activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma nitrate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma nitrite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of severe EA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in CFUs/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ABI-pe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain score differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival to hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: maximum pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in EPDS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NPI agitation domain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mADCS‐CGIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive improvement measured by MMSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global improvement measured by CIBIC-plus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cumulative 24h morphine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the pain intensity‐time‐curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular mortality or morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prostate-specific antigen (PSA) decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality due to prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Toxicities grade ≥ 3
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction rating from practice members
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduction in alcohol misuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of any-grade treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Drug cessation or dosage decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in TWSTRS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients expressing greatest satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in hospital bed use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: pain intensity difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain remission degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dropped level of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Independence Measure scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Atheroma Volume (TAV) regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Atheroma Volume (PAV) regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: missed days of school because of illness per 100 days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: neutrophil phagocytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: monocyte mCD14 and HLA‐DR expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LPS‐induced TNF‐alpha production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in goitre volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypothyroidism post-RAI
Endpoint domain: Adverse events/effects
Primary endpoint: Retention properties of fissure sealant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microleakage percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of phobic fears and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrinsic heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in clinical symptoms of burning sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in skin irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: hair counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hair coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in dyspeptic symptoms after HP-eradication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neutrophil infiltration in the gastric mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: megacode performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-Hsp antibodies levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage time with pH > 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of subjects with nocturnal acid breakthrough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step length of the paretic limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step length of the non‐paretic limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip flexion at mid swing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient discomfort on insertion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient discomfort on removal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Insertion graded by the clinician
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of contaminated body sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contamination score measured by ultraviolet light visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean teamwork score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: serum BALP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urine NTX levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BALP/NTX ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rate of treatment for postural clubfoot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: decreased disturbances to physical activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevention of dental hypersensitiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VISA-G score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AG suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: global symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropsychiatric disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of anxiety and depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable disease at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of progression of renal impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Conversion to normal sinus rhythm (NSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average time to conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to first lapse
Endpoint domain: Mortality/survival
Primary endpoint: time to first relapse
Endpoint domain: Mortality/survival
Primary endpoint: Muscular activity during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of fatal or nonfatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of major cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Mean LDL cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: measurable effect of 1.5‐T brain MR imaging on MEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: diagnostic confidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dose savings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: firmness of erection during coitus
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: contentedness with sexual functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: satisfaction with own sexuality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: diagnosed opioid abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nodal yield values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined CR/nCR rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Health score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Consumption of unhealthy foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of negative effect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: median attenuation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of heart failure (HF)
Endpoint domain: Mortality/survival
Primary endpoint: Mood profile improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in pain medication prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in work status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Complete or partial remission of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute left heart failure
Endpoint domain: Adverse events/effects
Primary endpoint: Guanidinosuccinate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation markers (CRP, PINI-score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum total bilirubin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: jaundice resolution time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemoglobin level after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients achieving sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Organism MIC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of doxycycline-resistant isolates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of multi-antibiotic resistance
Endpoint domain: Adverse events/effects
Primary endpoint: Response to opioid overdoses
Endpoint domain: Mortality/survival
Primary endpoint: enamel surface loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correct jejunal tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients who remained relapse-free at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responsibility attribution
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Worthy of help attribution
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dangerousness attribution
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ED95 values for mivacurium and pancuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement of mivacurium reduced by > 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TOF ratio of 0.70 in 9.5 +/- 3.9 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prediction probability of weighted spectral median frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cholestatic indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness of PA facilities
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: packed red cell transfusion requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of critical care stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resuscitation skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of infusion-related adverse events (IRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Efficiency in identifying indirect vision points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in identifying indirect vision points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of dental hygiene treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: lower-extremity functional capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted geometric mean ratios of empagliflozin AUC(0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted geometric mean ratios of empagliflozin C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted geometric mean ratios of metformin AUC(0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted geometric mean ratios of metformin C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported mental fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: serum IGF1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Risk of dying of IHD
Endpoint domain: Mortality/survival
Primary endpoint: Frequency and severity of asphyxia attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Temporary disability duration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Haemoglobin A1c control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Timed-Up-and-Go distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxygen consumption rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faecal EPSs concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: intestinal permeability (L/M ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: adhesive failures
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of volume delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual C difficile counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Value of Statistical Life Year (VSLY)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in overnight plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eligibility for RT-qPCR analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of multicentre analysis of gene transcripts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of SIJ pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of fibromyalgia tender points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interrater reliability for SIJ pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes